Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corporation (Nasdaq: LFVN) is a health and wellness company centered on nutrigenomics and cellular activation, and its news flow reflects this focus. The company regularly issues updates on its activator-based product portfolio, consultant community, scientific research, and participation in investor and industry events. As the Activation company, LifeVantage highlights how its products, such as the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, and the comprehensive gut activator P84, fit into broader wellness systems and scientific narratives.
News about LifeVantage often covers new product launches and enhancements, including additions to its activation-supporting nutrients, AXIO nootropic energy drink mixes, and TrueScience skin and hair care line. Company communications also describe major field events like Momentum Academy and Global Kickoff, where Consultants receive training, hear about new tools, and learn strategies related to enrollment, retention, and advancement. These events frequently coincide with the introduction of new offerings or the integration of acquired product lines such as LoveBiome’s P84.
Investors following LFVN can also expect announcements on quarterly and annual financial results, dividend declarations, share repurchase activity, and guidance ranges, as well as notices of participation in conferences and fireside chats. The company’s releases include commentary from management on strategic initiatives such as integrating LoveBiome assets, expanding its wellness ecosystem, and advancing digital capabilities like the Daily Activation app.
This news page aggregates these updates so readers can track developments in LifeVantage’s product science, consultant network, and corporate strategy in one place. For anyone monitoring LFVN stock, the consultant-driven business model, or trends in nutrigenomics-focused wellness products, the news feed provides an ongoing view of how the company communicates its progress and priorities.
LifeVantage (Nasdaq: LFVN), a leader in health and wellness, announced its participation in the Water Tower Fireside Chat Series on December 3, 2024. The event will feature presentations by Steve Fife, President and CEO, and Carl Aure, CFO, scheduled for 11:00 a.m. Eastern Time. The presentation will be webcasted and accessible via the company's Investor Relations website at https://lifevantage.gcs-web.com/.
LifeVantage (Nasdaq: LFVN) has reintroduced its TrueScience® TruePout Hydrating Lip Oil to the US market for Cyber Monday. The product is being sold as a three-pack with French Vanilla flavor and features plant-based ingredients. The lip oil offers hydration through plant-based squalane, exfoliation via pineapple extract, and nourishment from seed oils and fruit extracts. Available pricing tiers include Consultant Price at $75.99, Subscription Price at $85.49, and Retail Price at $94.99. The product is available exclusively through US Consultants and the LifeVantage website while supplies last.
LifeVantage (Nasdaq: LFVN), a health and wellness company focusing on cellular-level health products, has announced its participation in the upcoming Sidoti Micro Cap Conference. Steve Fife, President and CEO, and Carl Aure, CFO, will conduct virtual investor meetings and deliver a presentation on November 13, 2024, at 1:00 p.m. Eastern Time. The presentation will be available via live webcast through the company's Investor Relations website.
LifeVantage reported Q1 fiscal 2025 results with revenue of $47.2 million, down 8.1% year-over-year. Net income per diluted share increased to $0.14 from $0.05 in the prior year. The company launched the MindBody GLP-1 System™ on October 11th. Revenue declined 4.2% in Americas and 19.7% in Asia/Pacific & Europe. Despite lower revenues, adjusted EBITDA improved 11% to $4.4 million. The company maintains its fiscal 2025 guidance of $200-210 million in revenue and adjusted earnings per share of $0.70-$0.80.
LifeVantage (Nasdaq:LFVN) has announced that its Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock. The dividend will be paid on December 16, 2024 to stockholders of record at the close of business on December 2, 2024. LifeVantage is a health and wellness company focusing on products that activate optimal health processes at the cellular level.
LifeVantage (LFVN) announced results from a human clinical trial of their MindBody GLP-1 System™, showing a 140% average increase in GLP-1 levels and significant weight loss outcomes. The 12-week study involved 60 subjects with BMI≥25, divided into three groups. Key findings include: 92% of participants lost weight (average 11 pounds), 92% reduced total body fat, and 71% decreased visceral fat. Notably, participants reported improved relationships with food, with 95% experiencing decreased sugar cravings and 96% reducing portion sizes. The system uses natural ingredients to activate GLP-1 production without reported side effects.
LifeVantage (Nasdaq: LFVN), a health and wellness company focusing on cellular-level health products, has announced its participation in the LD Micro Main Event XVII. The event will take place from October 28-30, 2024, in Los Angeles, CA. Steve Fife, President and CEO, and Carl Aure, CFO, will conduct investor meetings and deliver a presentation on October 30, 2024, at approximately 4:30 p.m. Eastern Time. The presentation will be available via live webcast on the company's Investor Relations website.
LifeVantage (Nasdaq:LFVN), a health and wellness company focusing on cellular health, has announced it will release its first quarter fiscal year 2025 financial results on October 29, 2024, after the stock market closes. The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day.
Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers. A telephone replay will be available until November 12, 2024. Additionally, a live webcast will be accessible on the company's Investor Relations website, with an archive available for approximately 30 days.
LifeVantage (Nasdaq: LFVN) has launched its patent-pending MindBody GLP-1 System™ in the U.S., a dual-product solution designed to balance hunger hormones and support sustainable weight management. The system includes MB Core™ and MB Enhance™, which together increase natural GLP-1 production by an average of 140%.
Clinical trials showed that the system helped participants lose up to 27% of visceral fat and 5% of total body fat while maintaining muscle. The product launch at Market Connect in Kansas City met with high demand, with on-site products selling out quickly and e-commerce sales exceeding forecasts.
The MindBody GLP-1 System™ works by increasing GLP-1 production, activating GLP-1 receptor sites, and reducing the activity of enzymes that break down GLP-1. This approach aims to provide a comprehensive solution for long-term weight management and overall wellness.
LifeVantage (Nasdaq: LFVN) has announced enhancements to its Evolve Compensation Plan, set to launch on November 1, 2024, in the U.S., Japan, Australia, New Zealand, Canada, Mexico, and European markets. The updated plan aims to simplify and increase earning potential for independent LifeVantage Consultants.
Key features include:
- A new Sharing Bonus offering 10% commission for sharing LifeVantage products
- Double Sharing Bonus (up to 20%) for new Consultants in their first four months
- A bonus for reaching the Senior Consultant 1 rank
These changes are designed to provide greater simplicity and early income success for Consultants. The company also teased an upcoming launch of an innovative weight management system that naturally activates GLP-1.